FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia

Larimar Therapeutics, Inc.

FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.
OLE study continues at 25 mg; dose escalation to 50 mg planned after further frataxin PD characterization.
Interim OLE data expected Q4 2024; BLA submission targeted for 2H 2025.
In 50 mg cohort, all evaluable patients achieved skin frataxin >33% of healthy volunteer average at Day 14.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.